CYCN Cyclerion Therapeutics Inc.

3.01
-0.24  -7%
Previous Close 3.25
Open 3.2
Price To Book 0.86
Market Cap 83,542,231
Shares 27,754,894
Volume 127,505
Short Ratio
Av. Daily Volume 500,339
Stock charts supplied by TradingView

NewsSee all news

  1. Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases

    – Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and additional translational

  2. Cyclerion to Present at the J.P. Morgan Healthcare Conference

    – Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases – CAMBRIDGE, Mass., Dec. 23,

  3. Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for

  4. Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

    – Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to pursue out-license of

  5. Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

    CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due mid-2020.
Olinciguat (IW-1701) - STRONG-SCD
Sickle Cell disease
Phase 2 trial did not meet primary endpoint - October 30, 2019.
IW-1973 (Praliciguat)
Diabetic nephropathy
Phase 2 trial did not meet primary endpoint - October 30, 2019.
IW-1973 (Praliciguat)
Heart failure HFpEF
Phase 1 translational pharmacology top-line data due mid-2020.
IW-6463
Healthy volunteers

Latest News

  1. Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases

    – Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and additional translational

  2. Cyclerion to Present at the J.P. Morgan Healthcare Conference

    – Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases – CAMBRIDGE, Mass., Dec. 23,

  3. Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for

  4. Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

    – Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to pursue out-license of

  5. Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

    CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of

  6. Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

    CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for